Luoxin Pharmaceuticals Group Stock Co., Ltd. Share Price

Equities

002793

CNE1000026S7

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
4.32 CNY -0.46% Intraday chart for Luoxin Pharmaceuticals Group Stock Co., Ltd. +6.93% -19.40%

Financials

Sales 2022 3.59B 495M 39.55B Sales 2023 2.36B 326M 26.06B Capitalization 5.83B 805M 64.26B
Net income 2022 -1.23B -169M -13.52B Net income 2023 -661M -91.23M -7.29B EV / Sales 2022 2.93 x
Net Debt 2022 2.17B 300M 23.93B Net Debt 2023 798M 110M 8.8B EV / Sales 2023 2.8 x
P/E ratio 2022
-8.92 x
P/E ratio 2023
-8.79 x
Employees 4,582
Yield 2022 *
-
Yield 2023
-
Free-Float 55.27%
More Fundamentals * Assessed data
Dynamic Chart
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology MT
Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback announced on February 2, 2024, has closed with 26,027,861 shares, representing 2.39% for CNY 99.99 million. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. authorizes a Buyback Plan. CI
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial MT
Two Luoxin Pharma Drugs Selected in China’s National Drug Procurement Program MT
Luoxin Health Technology Development Co., Ltd. announced that it has received CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. agreed to acquire additional unknown stake in Luoxin Health Technology Development Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP) and Deyi Investment Management Co., Ltd. for CNY 1. CI
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day-0.46%
1 week+6.93%
Current month-6.09%
1 month-5.26%
3 months-14.46%
6 months-25.65%
Current year-19.40%
More quotes
1 week
4.05
Extreme 4.05
4.42
1 month
3.90
Extreme 3.9
4.69
Current year
3.41
Extreme 3.41
5.80
1 year
3.41
Extreme 3.41
7.15
3 years
3.41
Extreme 3.41
11.45
5 years
3.41
Extreme 3.41
18.89
10 years
3.41
Extreme 3.41
18.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 38 22/04/20
Director of Finance/CFO 41 07/07/21
Director/Board Member 42 30/01/23
Members of the board TitleAgeSince
Corporate Secretary 49 22/04/20
Chairman 44 30/01/23
Director/Board Member 76 18/05/21
More insiders
Date Price Change Volume
26/04/24 4.32 -0.46% 8,492,532
25/04/24 4.34 +3.09% 18,942,610
24/04/24 4.21 -0.24% 6,845,830
23/04/24 4.22 +3.94% 13,130,550
22/04/24 4.06 +0.50% 5,204,900

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Luoxin Pharmaceuticals Group Stock Co Ltd, formerly Zhejiang Doyin Pump Industry Co Ltd, is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates two segments. The Pharmaceutical Industry segment is engaged in the research and development, manufacturing and sales of chemical drug preparations and raw and auxiliary drugs. Its main products are digestive drugs, respiratory drugs and antibiotic drugs, among others. The Pharmaceutical Business segment is engaged in the sales and logistics of agent drugs and medical devices. The Company conducts its businesses in the domestic market.
More about the company
  1. Stock Market
  2. Equities
  3. 002793 Stock